Gilead Sciences ((GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The recent update from Gilead Sciences involves a clinical study titled A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects With Chronic Hepatitis B Virus Infection. The study aims to evaluate the effectiveness, safety, and tolerability of Tenofovir Alafenamide (TAF) compared to a placebo in children and teens with chronic hepatitis B, focusing on optimal dosing levels.
The intervention being tested is Tenofovir Alafenamide (TAF), an antiviral drug administered orally once daily. It is intended to treat chronic hepatitis B virus infection in children and adolescents.
This interventional study is designed as a randomized, double-blind trial with a parallel assignment. The primary purpose is treatment, with both participants and investigators masked to the treatment allocation.
The study began in November 2016, with the primary completion date not yet reached. The last update was submitted in July 2025. These dates indicate the ongoing nature of the study and its progress over time.
The market implications of this study could be significant for Gilead Sciences, potentially impacting its stock performance positively if the results are favorable. The study’s progress may influence investor sentiment, especially in the context of competition within the pharmaceutical industry for effective hepatitis B treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.